Menotropin (Synonyms: Human Menopausal Gonadotrophin) |
Catalog No.GC25627
One-Click Copy Product Info
|
Menotropin is a gonadotropin drug extracted from the urine of postmenopausal women, containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 61489-71-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Menotropin is a gonadotropin drug extracted from the urine of postmenopausal women, containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Menotropin can stimulate ovarian follicular development and maturation by binding to FSH receptors, while activating LH receptors to promote estrogen secretion and trigger ovulation. Menotropin can be used in research related to female anovulatory infertility and male hypogonadotropic hypogonadism[1-4].
In vitro, Menotropin (0.1-100mIU/ml) was used to treat SKOV-3 human ovarian carcinoma cells for 6 hours. Menotropin did not significantly affect urokinase plasminogen activator secretion[5]. Menotropin (10mIU/ml) was used to treat human granulosa cells for 48 hours. Menotropin significantly increased progesterone concentrations in the medium and cytoplasm, and enhanced microsomal 3β-hydroxysteroid dehydrogenase activity[6].
In vivo, Menotropin (15IU; single injection) was administered intraperitoneally to immature female Sprague Dawley albino rats at 28 days of age. Menotropin induced ovulation in rats over two consecutive days[7]. Menotropin (5IU/day) was administered intraperitoneally to 6-week-old BALB/C mice for 5 days. Menotropin significantly increased serum follicle-stimulating hormone and luteinizing hormone levels in mice, enlarged follicular volume, thickened granulosa cells, and promoted corpus luteum formation[8].
References:
[1] Li J, Peng Y, Dai X, et al. Human menopausal gonadotropin (HMG) combined different doses of letrozole for treating anovulatory infertility in patients with polycystic ovary syndrome: a randomized controlled trial. J Assist Reprod Genet. 2025 Jun;42(6):1895-1906.
[2] Daya S. WITHDRAWN: Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles. Cochrane Database Syst Rev. 1996 Apr 22;(1):CD000061.
[3] Levi Setti PE, Alviggi C, Colombo GL, et al. Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation. J Endocrinol Invest. 2015 May;38(5):497-503.
[4] Baer G, Loumaye E. Comparison of recombinant human luteinising hormone (r-hLH) and human menopausal gonadotropin (hMG) in assisted reproductive technology. Curr Med Res Opin. 2003;19(2):83-8.
[5] McDonnel AC, Murdoch WJ. High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane. J Steroid Biochem Mol Biol. 2001 Aug;78(2):185-91.
[6] Riccetti L, Klett D, Ayoub MA, et al. Heterogeneous hCG and hMG commercial preparations result in different intracellular signalling but induce a similar long-term progesterone response in vitro. Mol Hum Reprod. 2017 Oct 1;23(10):685-697.
[7] Koyama T, Hagino N, Cothron AW, et al. Effect of toki-shakuyaku-san on ovulation induced by human menopausal gonadotropin in rats. Am J Chin Med. 1988;16(3-4):169-72.
[8] Wen X, Xie J, Zhou L, et al. The role of combining medroxyprogesterone 17-acetate with human menopausal gonadotropin in mouse ovarian follicular development. Sci Rep. 2018 Mar 13;8(1):4439.
| Cell experiment [1]: | |
Cell lines | SKOV-3 human ovarian carcinoma cells |
Preparation Method | SKOV-3 cells were propagated to confluence in T-75 flasks at 37°C under 5% CO₂ in RPMI-1640 medium supplemented with 10% charcoal-stripped/heat-inactivated fetal calf serum, 10μg/ml insulin, and 1% antibiotic/antimycotic solution. Cells were transferred into 24-well flat-bottom plates and subcultured overnight. Media were removed from monolayers and replaced with 1ml serum/phenol red-free media containing Menotropin treatments. |
Reaction Conditions | 0.1-100mIU/ml; 6 hours |
Applications | Menotropin did not affect urokinase plasminogen activator secretion by SKOV-3 ovarian carcinoma cells during the 6-hour incubation period. |
| Animal experiment [2]: | |
Animal models | Sprague Dawley albino immature female rats |
Preparation Method | Fifteen international units of the Menotropin was injected intraperitoneally on the morning of 28 days of age, and ovulation (presence of tubal ova) was examined on the morning of 29, 30 and 31 days of age. |
Dosage form | 15IU; intraperitoneal injection; single injection on day 28 of age |
Applications | Menotropin alone induced ovulation in 70% of rats at 29 days of age, in 35% of rats at 30 days of age, and no ovulation was observed at 31 days of age. |
References: | |
| Cas No. | 61489-71-2 | SDF | |
| Synonyms | Human Menopausal Gonadotrophin | ||
| Formula | C9H18O | M.Wt | 142.24 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 7.0304 mL | 35.1519 mL | 70.3037 mL |
| 5 mM | 1.4061 mL | 7.0304 mL | 14.0607 mL |
| 10 mM | 703 μL | 3.5152 mL | 7.0304 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Potency: 233IU/mg Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)